Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

Medicine, Hematology, Oncology +16

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text

Medicine, Cancer Biology, Oncology +14

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

Eleni D. Lagadinou, Alexander Sach, Kevin P. Callahan et al. · Cell stem cell · 2013 · 1.4K citations · Full text

Life Sciences, Cell Biology, Oncology +12

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri et al. · Cancer Discovery · 2016 · 1.1K citations · Full text

Medicine, Hematology, Pharmacology +17

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al. · Journal of Clinical Oncology · 2017 · 751 citations

Medicine, Hematology, Pharmacokinetics +15